Compare IH & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | RANI |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 134.6M |
| IPO Year | 2020 | 2021 |
| Metric | IH | RANI |
|---|---|---|
| Price | $2.19 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 9.3K | ★ 2.6M |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $123,215,612.00 | $1,200,000.00 |
| Revenue This Year | $39.02 | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $7.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $0.39 |
| 52 Week High | $3.60 | $3.87 |
| Indicator | IH | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 42.10 |
| Support Level | $2.15 | $1.40 |
| Resistance Level | $2.40 | $1.53 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 21.44 | 15.00 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.